L. M. Evans
University Hospital of Wales
11 Papers
196 Citations
L. M. Evans is an academic researcher from University Hospital of Wales. The author has contributed to research in topics: Bromocriptine & Dopamine agonist. The author has an hindex of 8, co-authored 11 publications.
Chat about Author
Papers
Effects of GH replacement on endothelial function and large‐artery stiffness in GH‐deficient adults: a randomized, double‐blind, placebo‐controlled study
J. C. Smith,L. M. Evans,I Wilkinson,Jonathan Goodfellow,John R. Cockcroft,Maurice F. Scanlon,Jeffrey S. Davies +6 more
TL;DR: Hypopituitary adults with growth hormone deficiency (GHD) have an increased cardiovascular mortality, although the mechanisms remain unclear.
146
Endothelial dysfunction in hypopituitary adults with growth hormone deficiency
TL;DR: A noninvasive method is used to assess endothelial function in the brachial arteries of a group of treated hypopituitary adults with GHD, and agroup of healthy age‐and sex‐matched controls.
137
Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency.
TL;DR: Untreated growth hormone deficiency is implicated in the increased cardiovascular risk associated with adult hypopituitarism and Oxidative stress, predisposing to lipid peroxidation, may be an important mediator of endothelial dysfunction, a pro‐atherogenic state associated withadult GHD.
27
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
M Biswas,J. C. Smith,Deepak R Jadon,P. Mcewan,D. A. Rees,L. M. Evans,Maurice F. Scanlon,J. S. Davies +7 more
- 01 Mar 2004
TL;DR: In this paper, the authors performed a retrospective analysis of 89 patients, 84 women and 5 men with a mean age of 33 years, who were analyzed in 67 patients treated with 0.5 to 3 mg cabergoline weekly and 22 others given 2.5-10 mg bromocriptine daily.
20
The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia.
TL;DR: To test the hypothesis that patients with hyperprolactinaemia due to biologically inactive macroProlactin will not show the characteristically increased dopaminergic inhibition of TSH release seen in patients with microproLactinomas, a small number of patients secreting biologically active monomeric PRL are studied.
10